Pan-KRAS targeting drugs currently in clinical trials
| Drug | Sponsor | Disease setting | Clinical trial/phase |
|---|---|---|---|
| JAB-23E73 | Jacobio Pharmaceuticals | Monotherapy (NSCLC, CRC, PDAC, and others) | NCT06973564 phase 1/2 |
| AMG 410 | Amgen | Monotherapy or combination with (NSCLC, CRC, PDAC, and others): Panitumumab (CRC and PDAC) Pembrolizumab (advanced or metastatic solid tumors with KRAS mutations) | NCT07094113 phase I |
| BGB-53038 | BeiGene | Monotherapy or combination with (advanced or metastatic solid tumors with KRAS mutations or amplifications): Tislelizumab (NSCLC) Cetuximab (CRC) | NCT06585488 phase I |
| BI-3706674 | Boehringer Ingelheim | Monotherapy (GAC, EAC, and GEJAC) | NCT06056024 phase I |
| PF-07934040 | Pfizer | Monotherapy (NSCLC, CRC, and PDAC) or combination with: Gemcitabine + Nab-paclitaxel (PDAC) Cetuximab (CRC) FOLFOX + bevacizumab (CRC) Pembrolizumab (NSCLC) Pembrolizumab + platinum chemotherapy (NSCLC) | NCT06447662 phase I |
| LY-4066434 | Eli Lilly and Company | Monotherapy or combination with (advanced or metastatic solid tumors with KRAS mutations): Cetuximab Nab-paclitaxel Gemcitabine Oxaliplatin Leucovorin Irinotecan 5-Fluorouracil Carboplatin Cisplatin Pemetrexed Pembrolizumab | NCT06607185 phase I |
| YL-17231 | Shanghai YingLi Pharmaceutical Co., Ltd. | Monotherapy (advanced solid tumors bearing mutations in KRAS, HRAS, or NRAS) | NCT06096974 phase I |
CRC, colorectal cancer; EAC, esophageal adenocarcinoma; GAC, gastric adenocarcinoma; GEJAC, gastroesophageal junction adenocarcinoma; NSCLC, non-small cell lung cancer; PDAC, pancreatic ductal adenocarcinoma.